Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Araccel Audited Report for the Quarter and Year Ended December 31, 2001.


Business Editors/Health & Medical Writers

HORSHAM Horsham (hôr`shəm), town (1991 pop. 38,356) and district, West Sussex, SE England. Horsham is known primarily for its agricultural and merchandising activities, but it also serves as an engineering center. , Pa.--(BW HealthWire)--Feb. 28, 2002
-- New orders of 14 MSEK were received in January and February 2002, which
increases contract backlog to 37 MSEK.

-- Araccel's chief financial officer who is based in the US has resigned
effective March 15, 2002. A search for a new chief financial officer is
ongoing.


-11.6 MSEK MSEK Meyer, Suozzi, English & Klein (New York law firm)
MSEK Million Swedish Kroner
 (-5.2 MSEK) and -34.0 MSEK (-23.1 MSEK),

respectively.


-- New orders of 14 MSEK were received in January and February 2002, which
increases contract backlog to 37 MSEK.

-- Araccel's chief financial officer who is based in the US has resigned
effective March 15, 2002. A search for a new chief financial officer is
ongoing.


Important events during the fourth quarter


-- New orders of 14 MSEK were received in January and February 2002, which
increases contract backlog to 37 MSEK.

-- Araccel's chief financial officer who is based in the US has resigned
effective March 15, 2002. A search for a new chief financial officer is
ongoing.


Important events since the end of the year


-- New orders of 14 MSEK were received in January and February 2002, which
increases contract backlog to 37 MSEK.

-- Araccel's chief financial officer who is based in the US has resigned
effective March 15, 2002. A search for a new chief financial officer is
ongoing.

Future reporting dates for 2002:

May 6, 2002           Quarter ended March 31, 2002
Aug. 22, 2002         Quarter and six months ended June 30, 2002
Nov. 7, 2002          Quarter and nine months ended September 30, 2002
Feb. 28, 2003         Quarter and year ended December 31, 2002


It is anticipated that the annual report for 2001 will be accessible at Araccel's Stockholm Stockholm (stŏk`hôlm'), city (1995 pop. 692,954), capital of Sweden and of Stockholm co., E Sweden, situated where Lake Mälaren flows into the Baltic Sea.  office by April 5, 2002. The Annual General Meeting of shareholders is scheduled for May 6, 2002 at the Industrihuset, Storgatan 19, Stockholm at 5 p.m.

Araccel AB (publ)

Araccel AB is a global biomedical bi·o·med·i·cal
adj.
1. Of or relating to biomedicine.

2. Of, relating to, or involving biological, medical, and physical sciences.
 information technology company that provides clinical informatics Clinical Informatics is a sub-field of medical informatics. It focuses on computer applications that address medical data (collection, analysis, representation). Clinical informatics is a combination of information science, computer science, and clinical science designed to assist  solutions to the pharmaceutical industry to accelerate drug development.

The company develops and markets electronic research and development (e-R&D) pharmaceutical software and system solutions that captures clinical data, improves processes and provides metric reports on clinical trial data for enhancing and accelerating drug development.

Araccel AB is the market leader in its area and has 15 of the 20 largest pharmaceutical companies on its customer list. Araccel AB has its headquarters in Stockholm, Sweden Sweden, Swed. Sverige, officially Kingdom of Sweden, constitutional monarchy (2005 est. pop. 9,002,000), 173,648 sq mi (449,750 sq km), N Europe, occupying the eastern part of the Scandinavian peninsula.  and has operations in the US, UK, and Netherlands Netherlands (nĕth`ərləndz), Du. Nederland or Koninkrijk der Nederlanden, officially Kingdom of the Netherlands, constitutional monarchy (2005 est. pop. 16,407,000), 15,963 sq mi (41,344 sq km), NW Europe. , which operate under the name Araccel. The company has approximately ap·prox·i·mate  
adj.
1. Almost exact or correct: the approximate time of the accident.

2.
 2,700 stockholders and is quoted on the NGM See NetWare Global Messaging.  Equity list in Stockholm. Stocks are traded via D. Carnegie Carnegie (kärnĕg`ē, kär`nəgē), borough (1990 pop. 9,278), Allegheny co., SW Pa., an industrial suburb of Pittsburgh; inc. 1894. A steel town, it has coal mines and plants that make chemicals and electrical equipment.  AB.

REVENUE AND EARNINGS FOR THE THREE MONTHS ENDED DECEMBER December: see month.  31, 2001

The Group

Net revenues decreased during the fourth quarter of 2001 by 16% to 23.0 MSEK (27.3 MSEK), of which 71% came from the USA and 29% from Europe Europe (yr`əp), 6th largest continent, c.4,000,000 sq mi (10,360,000 sq km) including adjacent islands (1992 est. pop. 512,000,000). . New contract orders net of cancellations during the fourth quarter of 2001 amounted to -1.3 MSEK as compared to 21.6 MSEK for the comparable period in 2000.

The decline in new contract orders in the fourth quarter 2001 is primarily the result of the cancellation cancellation (See: cancel)


CANCELLATION. Its general acceptation, is the act of crossing a writing; it is used sometimes to signify the manual operation of tearing or destroying the instrument itself. Hyde v. Hyde, 1 Eq. Cas. Abr. 409; Rob.
 of $12.8 MSEK in monitoring services The general surveillance of known air traffic movements by reference to a radar scope presentation or other means, for the purpose of passing advisory information concerning conflicting traffic or providing navigational assistance.  to be provided in 2002 as a part of one of the Company's major contracts. The contract order backlog Backlog

The total value of sales orders waiting to be fulfilled.

Notes:
This figure is used mainly in the manufacturing industry. Increases or decreases in a company's backlog indicate the future direction of sales and earnings.
 decreased by 53% to 32.7 MSEK at the end of the December 2001 (70.0 MSEK at 12/31/2000).

The decline in contract backlog is due to slower sales in 2001 resulting from the transition of the Company to a new diary diary [Lat.,=day], a daily record of events and observations. As distinguished from memoir (an account of events placed in perspective by the author long after they have occurred), the diary derives its impact from its immediacy, requiring each generation of readers , the Araccel Evolution Clinical Digital Assistant, and a new software platform, the Araccel Solutions Platform (`ASPlatform") and the contract cancellation noted above.

Cost of services amounted during the quarter to 9.7 MSEK (15.5 MSEK), which resulted in a gross margin of 58% (43%). Sales and marketing costs were 8.6 MSEK (5.6 MSEK), general and administrative costs administrative costs,
n.pl the overhead expenses incurred in the operation of a dental benefits program, excluding costs of dental services provided.
 were 8.2 MSEK (9.4 MSEK) and research and development costs were 7.6 MSEK (4.6 MSEK). Included in research and development costs during Q4 2001 are increased personnel and related costs of 3.0 MSEK.

Net income (loss) after tax was -11.6 MSEK (-5.2 MSEK), which corresponds to -1.57 SEK SEK

In currencies, this is the abbreviation for the Swedish Krona.

Notes:
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion.
 per share (-0.71 SEK per share). The increase in the net loss is primarily a result of the 3.1 MSEK increase in sales and marketing costs due to the expansion of the European European

emanating from or pertaining to Europe.


European bat lyssavirus
see lyssavirus.

European beech tree
fagussylvaticus.

European blastomycosis
see cryptococcosis.
 sales force, and the 3.0 MSEK increase in R&D expenses.

The increase in R&D expenses are the result of continued development of the ASPlatform and the Company's new electronic diary, the Araccel Evolution Clinical Digital Assistant in 2001.

Parent Company

Operations in the parent company, Araccel AB (publ) mainly consists group management and assets consist of investments in shares of subsidiary's and intangible assets Intangible Asset

An asset that is not physical in nature.

Notes:
Examples are things like copyrights, patents, intellectual property, and goodwill. These are the opposite of tangible assets.
. Net revenues of the parent company during the fourth quarter were 3.4 MSEK with earnings (loss) after financial net of -3.9 MSEK. The cash position of the parent company was 3.9 MSEK at December 31, 2001(3.8 MSEK at 12/31/2000).

REVENUE AND EARNINGS FOR THE YEAR ENDED DECEMBER 31, 2001

The Group

Net revenues decreased by 9% during the year ended December 31, 2001 to 95.2 MSEK (104.8 MSEK), of which 56% came from the USA and 44% from Europe. New contract orders net of cancellations during the year ended December 31, 2001 amounted to 55.2 MSEK as compared to 110.2 MSEK for the comparable period in 2000, a decrease of 50%.

The contract order backlog decreased by 53% to 32.7 MSEK at the end of the December 2001 (70.0 MSEK at 12/31/2000). The decline in new orders and backlog are due to the transition of the Company to a new diary, the Araccel Evolution Clinical Digital Assistant, and a new software platform, the Araccel Solutions Platform (`ASPlatform") during 2001.

Cost of services during the year ended December 31,2001 amounted to 35.9 MSEK (51.3 MSEK), which resulted in a gross margin of 62% (51%). Sales and marketing costs were 27.2 MSEK (22.5 MSEK), general and administrative costs were 33.2 MSEK (26.3 MSEK) and research and development costs were 29.4 MSEK (9.8 MSEK).

Included in research and development costs during the year ended December 31, 2001 are increased personnel and related costs of 13.3 MSEK and depreciation of goodwill and software of 6.4 MSEK.

Net income (loss) after tax was -34.0 MSEK (-23.1 MSEK), which corresponds to -4.59 SEK per share (-3.98 SEK per share). The net loss for the year ended December 31, 2001 is primarily a result of increased costs of R&D (19.7 MSEK).

The net loss in 2000 included a restructuring restructuring - The transformation from one representation form to another at the same relative abstraction level, while preserving the subject system's external behaviour (functionality and semantics).  reserve for the write-down Write-Down

Reducing the book value of an asset because it is overvalued compared to the market value.

Notes:
This is usually reflected in the company's income statement as an expense, thereby reducing net income.
 of goodwill and trademarks (6.3 MSEK) and global operations Global Operations is a first-person shooter computer game developed by Barking Dog Studios and published by both Crave Entertainment and Electronic Arts. It was released in March of 2002, following its public multiplayer beta version which contained only the Quebec map.  realignment re·a·lign  
tr.v. re·a·ligned, re·a·lign·ing, re·a·ligns
1. To put back into proper order or alignment.

2. To make new groupings of or working arrangements between.
 resulting from the Technilogix acquisition in April 2000 (10.1 MSEK).

Parent Company

Net revenues of the parent company were 14.0 MSEK (17.8 MSEK) with earnings (loss) after tax of -8.4 MSEK (3.2 MSEK).

FINANCIAL SITUATION

The Company generated operating cash flow Operating cash flow

Earnings before depreciation minus taxes. Measures the cash generated from operations, not counting capital spending or working capital requirements.
 from current operations of -1.4 MSEK during the year ended December 31, 2001 (-5.2 MSEK). Total depreciation and amortization expenses for the year ended December 31, 2001 was 19.0 MSEK (20.0 MSEK) and represents non-cash costs.

Cash at the end of the period amounted to 17.0 MSEK at December 31, 2001 (25.6 MSEK at December 31, 2000).

Solidity so·lid·i·ty  
n.
1. The condition or property of being solid.

2. Soundness of mind, moral character, or finances.

Noun 1.
 ratio declined to 67.2% (70.7% at 12/31/2000).

The number of shares outstanding at the end of December 2001 is 7,397,494 (7,397,494).

Investments during the year ended December 31, 2001 declined to 8.0 MSEK (58.9 MSEK) and consisted primarily of fixed assets fixed assets nplactivo sg fijo

fixed assets nplimmobilisations fpl

fixed assets fix npl
 in 2001. In 2000, investments included the acquisition of the assets of Technilogix and the ASPlatform.

PERSONNEL

At end of the December 31, 2001, the group employed 81 (94) full time people, all of which are outside of Sweden. The US operations had 53 (66) employees, the UK 16 (16) employees, and the Netherlands 12 (12) employees.

NAME CHANGE

During the second quarter, MiniDoc AB changed its name to Araccel AB to reflect the evolution of the company to a global biomedical information technology company focused on accelerating drug development through clinical informatics.

DIVIDENDS

The Board of Directors has decided that no dividends will be declared de·clare  
v. de·clared, de·clar·ing, de·clares

v.tr.
1. To make known formally or officially. See Synonyms at announce.

2. To state emphatically or authoritatively; affirm.

3.
 for 2001.

ACCOUNTING PRINCIPLES

This report has been done in accordance Accordance is Bible Study Software for Macintosh developed by OakTree Software, Inc.[]

As well as a standalone program, it is the base software packaged by Zondervan in their Bible Study suites for Macintosh.
 with Accounting Council recommendation RR 20 Interim Reporting. With the exception of what is stated below, the accounting principles are unchanged compared with the latest annual report. Certain reclassifications have been made for comparability between 2001 and 2000.

The Accounting Council recommendation RR9:Income Tax means, among other things, that the group account for net operating tax loss carry-forwards if there is a high likelihood that these tax deductions Tax deduction

An expense that a taxpayer is allowed to deduct from taxable income.


tax deduction

See deduction.
 can be utilized against future net taxable income Under the federal tax law, gross income reduced by adjustments and allowable deductions. It is the income against which tax rates are applied to compute an individual or entity's tax liability. The essence of taxable income is the accrual of some gain, profit, or benefit to a taxpayer. . The total amount of tax loss carry-forwards in the group amounts to approximately 175.7 MSEK at December 31, 2001 (144.6 MSEK at 12/31/2000).

The main components of the group tax loss carry-forwards are from the parent company, Araccel AB of approximately 91.3 MSEK (82.9 MSEK) (28% income tax rate) and Araccel Corporation, the American American, river, 30 mi (48 km) long, rising in N central Calif. in the Sierra Nevada and flowing SW into the Sacramento River at Sacramento. The discovery of gold at Sutter's Mill (see Sutter, John Augustus) along the river in 1848 led to the California gold rush of  subsidiary, of approximately 84.4 MSEK (61.7 MSEK (35% income tax rate).

As it is currently not certain that these tax loss carry-forwards will be utilized, the group has chosen not to account for any future tax benefit from these tax loss carry-forwards.

Stockholm, Sweden, February February: see month.  28, 2002 Araccel AB (publ) - organization number 556470-2065

Board of Directors


                              Araccel AB

                             Fourth Quarter          Twelve Months
Key Financial
 Information Summary       2001       2000        2001         2000
                        ----------------------------------------------

Summary of Consolidated
 Income Statement
 (KSEK):
Net revenues              22,983      27,318      95,231      104,771
Cost of services
 and hardware             -9,707     -15,521     -35,930      -51,251
                        ----------------------------------------------
Gross Profit              13,276      11,797      59,301       53,520
Sales and marketing       -8,650      -5,594     -27,221      -22,507
Research and
 development costs        -7,576      -4,621     -29,441       -9,788
General and
 administrative costs     -8,236      -9,369     -33,245      -26,311
Other income & expense       283         137          34          137
                        ----------------------------------------------
Operating profit (loss)  -10,902      -7,650     -30,572       -4,949
Group goodwill
 amortization             -1,015      -1,014      -4,060       -3,059
Items affecting
 comparability                 0       3,308           0      -14,129
                        ----------------------------------------------
Result before financial
 net and tax             -11,917      -5,356     -34,632      -22,137
Net finance income
 (expense)                   -69         158         272         -225
                        ----------------------------------------------
Net income (loss)
 before tax              -11,986      -5,198     -34,360      -22,362
Tax                          409           0         409         -708
                        ----------------------------------------------
Net income (loss)
 after tax               -11,577      -5,198     -33,951      -23,070
                        ----------------------------------------------
Other Information:
Results after tax
 per weighted
 average shares
 outstanding
 excluding
 outstanding
 warrants (SEK)           (1.57)      (0.71)      (4.59)       (3.98)
Results after tax
 per weighted
 average shares
 including
 outstanding
 warrants (SEK)           (1.28)      (0.58)      (3.75)       (3.10)
Equity per share
 excluding
 outstanding
 warrants (SEK)                                     7.44        11.56
Equity per share
 including
 outstanding
 warrants (SEK)                                    14.38        19.80
Debt ratio                                         10.0%         6.2%
Profit margin              57.8%       43.2%       62.3%        51.1%
Solidity ratio                                     67.2%        70.7%
Revenues per
 employee during
 the past 12
 months (KSEK)                                     1,088        1,435
Shares at period's
 end excluding
 outstanding warrants  7,397,494   7,397,494   7,397,494    7,397,494
Shares at period's
 end including
 outstanding warrants  9,047,494   9,047,494   9,047,494    9,047,494
Weighted average of
 shares excluding
 outstanding warrants  7,397,494   7,339,549   7,397,494    5,795,946
Weighted average of
 shares including
 outstanding warrants  9,047,494   8,989,549   9,047,494    7,445,946

Cost of services
 (% of revenues)           42.2%       56.8%       37.7%        48.9%
Sales and marketing
 (% of revenues)           37.6%       20.5%       28.6%        21.5%
Research and development
 (% of revenues)           33.0%       16.9%       30.9%         9.3%
General and
 administrative
 (% of revenues)           35.8%       34.3%       34.9%        25.1%



                                    12/31/2001        12/31/2000
                                   ------------------------------
Summary of Consolidated
 Balance Sheet (KSEK):
Assets
Software                              24,750            31,350
Goodwill                               6,193            12,225
Patient diaries                        2,287             3,765
Other fixed assets                    14,389            10,216
                                   ------------------------------
Total fixed assets                    47,618            57,556
Other current assets                  17,211            37,840
Cash in bank                          17,039            25,644
                                   ------------------------------
Total current assets                  34,250            63,484
                                   ------------------------------
Total assets                          81,868           121,040

Liabilities and
 stockholders' equity:
Stockholders' equity                  55,038            85,528
Long-term liabilities                  3,542             5,130
Current liabilities                   23,288            30,382
                                   ------------------------------
Total liabilities and
 stockholders' equity                 81,868           121,040

Changes in Stockholders' Equity:
Equity at beginning of the period     85,528           17,409
New issues                                 0           92,100
Currency translation differences       3,461             -911
Current period income (loss)         -33,951          -23,070
                                   ------------------------------
Stockholders' equity at
 end of the period                    55,038           85,528

Cash Flow Analysis Summary (KSEK):
Cash flow from the
 ongoing operation before
 changes in operating capital        -14,948             -887
Changes in operating capital          13,535           -4,335
                                   ------------------------------
Cash flow from current operations     -1,413           -5,222

Cash flow from investments            -8,003          -58,922

Cash flow from financing              -1,589           88,501

Currency translation differences       2,399              669
                                   ------------------------------

Change in cash flow during period     -8,606           24,357


Please visit the company's website www.araccel.com.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 28, 2002
Words:2262
Previous Article:Phillips-Van Heusen Corporation to Host Conference Call to Discuss Fourth and Year End Quarter Results.
Next Article:Charter Communications and HSA Close on Purchase Agreement.



Related Articles
IntraLinks and Araccel Corporation Ink Partnership Agreement; Global Biomedical Information Technology Company to Integrate Digital Workspaces.
Araccel Corporation Recognized as Number 1 in Frost & Sullivan: US Electronic Clinical Trials Market 2001.
Araccel AB Report for the Quarter and Nine Months Ended September 30, 2001.
Araccel Standardizes On MarketFirst Release 3 for Marketing Automation; MarketFirst Adds Global Pharmaceutical Company to Its Growing List of Life...
Araccel Corporation Wins $600,000 Contract for eClinical Trial Solution.
I-Flow Corporation Reports Fourth Quarter Results; Revenue for 2001 Rises to a Record $33.3 Million.
GraphOn Corp. Reports Fourth Quarter 2001 Results.
Araccel Completes Financing To Accelerate Growth Strategy.
Araccel Deploys ASFlash for 60 Site European Marketing Study.
Araccel Corporation Restructures and Recapitalizes With A New Round of Financing for Growth.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles